2,854 results match your criteria Hepatitis D


Hepatitis D infection: from initial discovery to current investigational therapies.

Gastroenterol Rep (Oxf) 2019 Aug 23;7(4):231-245. Epub 2019 Jun 23.

Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

Hepatitis D is the most severe form of viral hepatitis associated with a more rapid progression to cirrhosis and an increased risk of hepatocellular carcinoma and mortality compared with hepatitis B mono-infection. Although once thought of as a disappearing disease, hepatitis D is now becoming recognized as a serious worldwide issue due to improvement in diagnostic testing and immigration from endemic countries. Despite these concerns, there is currently only one accepted medical therapy (pegylated-interferon-α) for the treatment of hepatitis D with less than desirable efficacy and significant side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/gastro/goz023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691517PMC

N-terminal PreS1 Sequence Regulates Efficient Infection of Cell Culture-generated Hepatitis B Virus.

Hepatology 2020 May 23. Epub 2020 May 23.

Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.

Background & Aims: An efficient cell culture system for hepatitis B virus (HBV) is indispensable for research on viral characteristics and anti-viral reagents. Currently, for the HBV infection assay in cell culture, viruses derived from HBV genome-integrated cell lines of HepG2.2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.31308DOI Listing

Statin inhibits large hepatitis delta antigen-Smad3 -twist-mediated epithelial-to-mesenchymal transition and hepatitis D virus secretion.

J Biomed Sci 2020 May 21;27(1):65. Epub 2020 May 21.

Translational Research Division, Medical Research Department, Taipei Veterans General Hospital, No.201, Sec. 2, Shipai Rd., Beitou District, Taipei, 11217, Taiwan, Republic of China.

Background: Hepatitis D virus (HDV) infection may induce fulminant hepatitis in chronic hepatitis B patients (CHB) or rapid progression of CHB to cirrhosis or hepatocellular carcinoma. There is no effective treatment for HDV infection. HDV encodes small delta antigens (S-HDAg) and large delta antigens (L-HDAg). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12929-020-00659-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240974PMC

Seroconversion of HBsAG coincides with hepatitis A super-infection: A case report.

World J Clin Cases 2020 May;8(9):1651-1655

Department of Internal Medicine, Division of Infectious Disease, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.

Background: Hepatitis B virus (HBV) is a hepatotropic virus that can cause acute and chronic liver damage. According to the world health organization 257 million people are infected with chronic HBV infection worldwide. Super-infection with other hepadnaviruses, including hepatitis A virus (HAV), hepatitis C virus, hepatitis D virus, and hepatitis E virus is associated with increased risk of acute liver failure in patients with chronic HBV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12998/wjcc.v8.i9.1651DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211520PMC

Noninvasive Models for Predicting Liver Fibrosis in Individuals with Hepatitis D Virus/Hepatitis B Virus Coinfection in the Brazilian Amazon Region.

Am J Trop Med Hyg 2020 May 18. Epub 2020 May 18.

Oswaldo Cruz Institute of Rondônia, Porto Velho, Brazil.

Hepatitis D virus (HDV) genotype III is endemic in the western Amazon basin and is considered to cause the most severe form of chronic viral hepatitis. Recently, noninvasive fibrosis scores to determine the stage of liver fibrosis have been evaluated in individuals positive for HDV genotype I, but their utility in HDV genotype III-positive patients is unknown. In this retrospective study conducted in an outpatient viral hepatitis referral clinic in the Brazilian Amazon region, the aspartate aminotransferase (AST) to Aspartate aminotransferase to Platelet Ratio Index (APRI) and Fibrosis Index for Liver Fibrosis (FIB-4) values were calculated and compared with histological fibrosis stages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4269/ajtmh.19-0688DOI Listing

HDVdb: A Comprehensive Hepatitis D Virus Database.

Viruses 2020 May 14;12(5). Epub 2020 May 14.

Institute of Virology, Technische Universität München, 81675 Munich, Germany.

Hepatitis D virus (HDV) causes the most severe form of viral hepatitis, which may rapidly progress to liver cirrhosis and hepatocellular carcinoma (HCC). It has been estimated that 15-20 million people worldwide are suffering from the chronic HDV infection. Currently, no effective therapies are available to treat acute or chronic HDV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/v12050538DOI Listing

Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West.

Clin Res Hepatol Gastroenterol 2020 May 14. Epub 2020 May 14.

Service d'hépatologie, pôle d'activité cancérologique spécialisée, hôpitaux universitaires Paris Seine Saint-Denis, AP-HP, site Jean-Verdier, 93143 Bondy, France; Université Paris 13, Sorbonne Paris cité, Bobigny, France; Unité Inserm UMR1162, Paris, France. Electronic address:

Background: In Western countries, hepatocellular carcinoma (HCC) in hepatitis B (HBV) patients without cirrhosis was poorly studied. The aim was to describe the characteristics and outcome of HBV-related HCC according to fibrosis stage.

Method: All patients with chronic HBV infection and HCC discussed in a multidisciplinary tumor board between 2007 and 2017 were retrospectively included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinre.2020.03.030DOI Listing

Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg.

Sci Rep 2020 May 12;10(1):7837. Epub 2020 May 12.

The Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA.

Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) for its assembly and release. Current HBV treatments are only marginally effective against HDV because they fail to inhibit HBsAg production/secretion. However, monotherapy with the nucleic acid polymer REP 2139-Ca is accompanied by rapid declines in both HBsAg and HDV RNA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-64122-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217939PMC

Hepatitis Delta: Prevalence, Natural History, and Treatment Options.

Gastroenterol Clin North Am 2020 Jun;49(2):239-252

Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Room 4-5722, Bethesda, MD 20892, USA.

Half a century after its discovery, hepatitis delta remains a pertinent global health issue with a major clinical impact in endemic regions and an underestimated prevalence worldwide. Hepatitis delta virus infection follows a challenging clinical course and is responsible for significant liver-related morbidity. Although the only currently available treatment (pegylated interferon) does not provide consistent results, emerging therapeutic options are promising. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gtc.2020.01.004DOI Listing

TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection.

JHEP Rep 2020 Jun 10;2(3):100098. Epub 2020 Mar 10.

Gene Therapy and Regulation of Gene Expression Program, CIMA, University of Navarra, Instituto de Investigacion Sanitaria de Navarra, IdisNA, Pamplona, Spain.

Background & Aims: HDV infection induces the most severe form of human viral hepatitis. However, the specific reasons for the severity of the disease remain unknown. Recently, we developed an HDV replication mouse model in which, for the first time, liver damage was detected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhepr.2020.100098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200939PMC

The global prevalence of hepatitis D virus infection: systematic review and meta-analysis.

J Hepatol 2020 Apr 23. Epub 2020 Apr 23.

Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom. Electronic address:

Background And Aims: There are uncertainties about the epidemic patterns of hepatitis delta virus (HDV) infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among hepatitis B surface antigen (HBsAg)-positive people.

Methods: We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2020.04.008DOI Listing

Use of the LI-RADS classification in patients with cirrhosis due to infection with hepatitis B, C, or D, or infected with hepatitis B and D.

Radiol Bras 2020 Jan-Feb;53(1):14-20

Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.

Objective: To evaluate liver lesions, in accordance with the LI-RADS classification, using contrast-enhanced multiphase dynamic computed tomography in patients with hepatitis B, coinfected or not with hepatitis D, or with chronic hepatitis C, as well as to determine the level of agreement between radiologists.

Materials And Methods: We evaluated 38 patients with hepatitis B, coinfected or not with hepatitis D, or with chronic hepatitis C, all of whom underwent contrast-enhanced multiphase dynamic computed tomography. For each examination, two radiologists selected up to three hepatic lesions, categorizing them in accordance with the LI-RADS classification and evaluating signs of chronic liver disease and portal hypertension. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/0100-3984.2018.0077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159051PMC

Management of viral hepatitis A, C, D and E in pregnancy.

Best Pract Res Clin Obstet Gynaecol 2020 Mar 21. Epub 2020 Mar 21.

Department of Medicine, The University of Hong Kong, Hong Kong SAR, China.

Viral hepatitis can cause significant maternal and neonatal morbidity and mortality. Hepatitis A and E mainly present as acute hepatitis during pregnancy, while hepatitis C and D are usually found as chronic infection in pregnant women. Hepatitis A remains self-limiting during pregnancy while hepatitis E has a higher prevalence and manifests with a rigorous course in pregnant women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpobgyn.2020.03.009DOI Listing

Research news in clincal context.

Sex Transm Infect 2020 May;96(3):235-236

Saw Swee Hock School of Public Health, National University Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/sextrans-2019-054271DOI Listing

Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy.

J Gastroenterol Hepatol 2020 Apr 4. Epub 2020 Apr 4.

Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Background And Aim: The serial serologic changes of hepatitis D virus (HDV) infection among chronic hepatitis B virus (HBV) infected patients who received oral nucleotide/nucleoside analogues are elusive.

Methods: Serum anti-HDV and HDV RNA among chronic hepatitis B (CHB) patients were tested at the time of initiating anti-HBV therapy and subsequently during the follow-up period.

Results: The seropositive rate of anti-HDV and HDV RNA among 2850 CHB patients, was 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.15061DOI Listing

Snake Deltavirus Utilizes Envelope Proteins of Different Viruses To Generate Infectious Particles.

mBio 2020 Mar 17;11(2). Epub 2020 Mar 17.

University of Helsinki, Medicum, Department of Virology, Helsinki, Finland.

Satellite viruses, most commonly found in plants, rely on helper viruses to complete their replication cycle. The only known example of a human satellite virus is the hepatitis D virus (HDV), and it is generally thought to require hepatitis B virus (HBV) to form infectious particles. Until 2018, HDV was the sole representative of the genus and was thought to have evolved in humans, the only known HDV host. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/mBio.03250-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078484PMC

[Detection of markers of hepatitis B and D virus infection in biological media and dried blood spots.]

Klin Lab Diagn 2020 ;65(2):95-99

Russian Medical Academy of Continuous Professional Education, 125993, Moscow, Russia.

The aim of this study was to assess the rates of detection of the major markers of infection with hepatitis B and Delta (D) viruses in serum, saliva and dry blood dots (DBS) as a possible option for serological studies among the population of the endemic region in conditions of limited laboratory resources. For this purpose, paired samples of blood serum and DBS, blood serum and saliva from patients with chronic hepatitis B with Delta agent living in the Republic of Tyva, which is endemic for this disease. HBsAg was detected in 289 (100%) serum samples, in 88/92 (95. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18821/0869-2084-2020-65-2-95-99DOI Listing
January 2020

Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.

J Hepatol 2020 Mar 6. Epub 2020 Mar 6.

Division of Clinical Pathology, Geneva University Hospitals, Geneva, Switzerland; Division of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva, Switzerland. Electronic address:

Background & Aims: Chronic hepatitis D (CHD) is the most severe form of chronic viral hepatitis but its role in the development of hepatocellular carcinoma (HCC) remains debated. We conducted a systematic review and meta-analysis of epidemiological studies to examine whether CHD is associated with an increased risk of HCC.

Methods: We searched Pubmed, Embase and Web of Science, as well as study references and conference proceedings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2020.02.030DOI Listing

Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes.

Hepatology 2020 Mar 7. Epub 2020 Mar 7.

Department of Infectious Diseases, Karolinska University Hospital, Sweden.

Background & Aims: Hepatitis delta virus (HDV) infection is associated with fast progression to liver cirrhosis and liver complications. Previous studies have though been mainly from tertiary care centers, with risk for referral bias towards patients with worse outcomes. Furthermore, the impact of HDV viremia per se on liver-related outcomes is not really known outside HIV co-infection setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.31214DOI Listing

The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D.

Turk J Gastroenterol 2020 Feb;31(2):136-141

Department of Hepato-Gastroenterology, Dr. Ziauddin University Hospital Clifton, Karachi, Pakistan.

Background/aims: Sodium taurocholate co-transporting polypeptide (NTCP) is the receptor for the hepatitis B virus (HBV) and hepatitis D virus (HDV) entry into hepatocytes. Ezetimibe is a cholesterol-lowering drug that possesses the pharmacophore features to inhibit NTCP. This study evaluates the efficacy of ezetimibe in patients with chronic HDV infection in a nonrandomized trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/tjg.2020.18846DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062136PMC
February 2020
0.470 Impact Factor

Chronic Viral Hepatitis: Current Management and Future Directions.

Hepatol Commun 2020 Mar 20;4(3):329-341. Epub 2020 Jan 20.

Section of Hepatology Rush University Medical Center Chicago IL.

The past decade has seen transformation in the strategies for identifying and managing viral hepatitis, most dramatically the transformation of hepatitis C virus from a mostly chronic affliction to a curable disease that is accessible to wide populations through direct-acting antiviral therapies. More recently, shifting of hepatitis C virus burden to younger patients driven by intravenous drug use has shaped screening recommendations. Future work focusing on effective screening, linkage to care, treatment initiation, and post-cure management will allow countries to work toward meeting goals of eliminating viral hepatitis as a major public health threat. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep4.1480DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049676PMC

Treatment of hepatitis D: an unmet medical need.

Clin Microbiol Infect 2020 Feb 28. Epub 2020 Feb 28.

Department of Medical Sciences, University of Turin, Turin, Italy. Electronic address:

Background: Therapy of chronic hepatitis D (CHD) is still based on interferon alpha (IFNα), introduced in clinical practice 30 years ago: results are modest and better therapies are an urgent medical need.

Aims: This article provides a critical overview of the new therapies under investigation for CHD.

Sources: Review of the recently published medical literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmi.2020.02.031DOI Listing
February 2020

Prevalence of hepatitis D virus among HBsAg-positive individuals, 2015-2016: Azar cohort study.

Health Promot Perspect 2020 28;10(1):38-42. Epub 2020 Jan 28.

Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Hepatitis D virus (HDV) is a defective RNA pathogen that requires the presence of the hepatitis B virus (HBV) for infection. Middle East countries are endemic areas for HDV infection. So, it is important to estimate the prevalence of HDV in these countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15171/hpp.2020.07DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036205PMC
January 2020

The effect of Hepatitis D co-infection on the immunologic and molecular profile of Hepatitis B in asymptomatic Chronic Hepatitis B patients in southwest Nigeria.

J Immunoassay Immunochem 2020 May 25;41(3):272-280. Epub 2020 Feb 25.

Medical Microbiology, University of Ibadan College of Medicine, Ibadan, Nigeria.

: Hepatitis D infection causes severe form of viral hepatitis in humans and only affects those with hepatitis B either as a co-infection or superinfection. The aim of this study was to determine the prevalence of Hepatitis D and its effect on the immunologic and molecular profile of Hepatitis B among asymptomatic Chronic Hepatitis B patients in Abeokuta.: A cross-sectional study of 99 chronic HBV patient who met the inclusion criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15321819.2020.1728542DOI Listing

New epidemiology of hepatitis delta.

Liver Int 2020 Feb;40 Suppl 1:48-53

Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece.

Hepatitis D virus (HDV) is a defective pathogen that needs hepatitis B virus (HBV) for infection. Co-infection of HBsAg-positive individuals with HDV is commonly associated with a more rapid progression to cirrhosis, a higher incidence of hepatocellular carcinoma (HCC) and increased mortality. Initial studies have shown that about 5% of chronic HBV carriers worldwide (15-20 millions) were also infected with HDV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14357DOI Listing
February 2020

Hepatitis D virus in Uzbekistan.

Lancet Gastroenterol Hepatol 2020 Mar;5(3):238-240

Research Institute of Virology, Tashkent 100122, Uzbekistan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(19)30350-4DOI Listing

Hepatitis D virus: is it all in the family?

Gut 2020 Feb 14. Epub 2020 Feb 14.

Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/gutjnl-2019-320549DOI Listing
February 2020

High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort.

BMC Gastroenterol 2020 Jan 30;20(1):24. Epub 2020 Jan 30.

1st Department of Internal Medicine, University Medical Hospital Hamburg-Eppendorf, Martinistr 52, 20246, Hamburg, Germany.

Background: Chronic hepatitis delta virus (HDV) infection causes severe liver disease which often leads to cirrhosis and hepatocellular carcinoma (HCC). Aim of this study was to establish the disease severity and prognostic factors for disease outcome by analysing frequencies of clinical events and their correlation with baseline virological and biochemical parameters as well as interferon and nucleos(t)ide analogue treatment choice.

Methods: We studied a single-centre cohort of 49 anti-HDAg-positive patients with HBsAg persistence for at least 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12876-020-1168-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993357PMC
January 2020

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections.

J Infect Dis 2020 Jan 29. Epub 2020 Jan 29.

Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Background: Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer. A hallmark of chronic hepatitis B is a dysfunctional HBV-specific T cell response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jiaa036DOI Listing
January 2020
5.997 Impact Factor

Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting-authors' reply.

Aliment Pharmacol Ther 2020 02;51(4):484

Department of Mental and Physical Health and Preventive Medicine, University L. Vanvitelli, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15625DOI Listing
February 2020

Prevalence of antibodies against Hepatitis D virus (HDV) in blood donors in Northern Germany.

Transfus Apher Sci 2020 Jan 9:102721. Epub 2020 Jan 9.

Institute of Transfusion Medicine, University Hospital of Schleswig-Holstein, Lübeck, Germany.

Objective: To assess the prevalence of HDV infections in German blood donors.

Method: 167 donors with acute/chronic or resolved HBV infection and detectable antibodies against Hepatitis B core antigen (anti-HBc) were tested for antibodies against HDV (anti-HDV) by competitive ELISA. Samples with detectable anti-HDV or with HBsAg and/or HBV DNA were additionally investigated for HDV RNA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2020.102721DOI Listing
January 2020

Targeting the Host for New Therapeutic Perspectives in Hepatitis D.

J Clin Med 2020 Jan 14;9(1). Epub 2020 Jan 14.

Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMR_S1110, F-67000 Strasbourg, France.

Hepatitis D virus (HDV) is a small satellite virus of hepatitis B virus (HBV) requiring HBV infection to complete its life cycle. It has been recently estimated that 13% of chronic HBV infected patients (60 million) are co-infected with HDV. Chronic hepatitis D is the most severe form of viral hepatitis with the highest risk to develop cirrhosis and liver cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9010222DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019876PMC
January 2020

Oncogenic Viral Infections Among Iranian Hemodialysis Patients: A Systematic Review.

Int J Prev Med 2019 10;10:216. Epub 2019 Dec 10.

Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Introduction: Chronic hemodialysis is a lifesaving procedure for end-stage renal failure patients who may lead to the transmission of oncogenic viral infections discussed as a major cause of liver disease and a potential cause of substantial morbidity and mortality. In this regard, the hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common infections that studied recently. This study aimed to review systematically all available documents on the prevalence of hepatitis D virus (HED), hepatitis E virus (HEV), hepatitis G virus (HGV), human T-lymphotropic virus (HTLV), human immunodeficiency virus (HIV), and Kaposi's sarcoma-associated herpes virus (KSHV) in Iranian hemodialysis patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijpvm.IJPVM_458_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941381PMC
December 2019

The epidemiology of hepatitis delta virus infection in Cameroon.

Gut 2020 Jan 6. Epub 2020 Jan 6.

Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France

Objective: To investigate the distribution and risk factors of hepatitis delta virus (HDV) infection in Cameroon.

Design: We tested for hepatitis B virus (HBV) surface antigen (HBsAg) and anti-HDV antibody 14 150 samples collected during a survey whose participants were representative of the Cameroonian adult population. The samples had already been tested for hepatitis C virus and HIV antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/gutjnl-2019-320027DOI Listing
January 2020

Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply.

Aliment Pharmacol Ther 2020 01;51(2):315-316

Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15614DOI Listing
January 2020

Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B?

Aliment Pharmacol Ther 2020 01;51(2):314-315

Department of General Surgery, Yan'An Hospital Affiliated to Kunming Medical University, Kunming, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15603DOI Listing
January 2020

Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Authors' reply.

Aliment Pharmacol Ther 2020 01;51(1):174-175

Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15558DOI Listing
January 2020

Editorial: rapid disease progression in hepatitis delta-can we turn the tide?

Aliment Pharmacol Ther 2020 01;51(1):172-173

Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15549DOI Listing
January 2020

The Delta-4 fibrosis score (D4FS): A novel fibrosis score in chronic hepatitis D.

Antiviral Res 2020 02 16;174:104691. Epub 2019 Dec 16.

Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address:

Background: Chronic Hepatitis D virus (HDV) infection results in the most severe form of viral hepatitis with a rapid progression to cirrhosis. However, non-invasive fibrosis tests that can accurately predict cirrhosis have not been adequately validated. We aimed to develop a clinically useful non-invasive score that can accurately detect cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.antiviral.2019.104691DOI Listing
February 2020

Seroprevalence of viral hepatitis A, B, C, D and E viruses in the Hormozgan province southern Iran.

BMC Infect Dis 2019 Dec 3;19(1):1027. Epub 2019 Dec 3.

Department of Clinical Virology, Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Namazi Hospital, Shiraz, Iran.

Background: Viral hepatitis is a global public health problem affecting millions of people worldwide, causing thousands of deaths due to acute and persistent infection, cirrhosis, and liver cancer. Providing updated serologic data can improve both surveillance and disease control programs. This study is aimed to determine the seroprevalence of markers for viral hepatitis (A, B, C, D and E) and the epidemiology of such infections in the general population of southern Iran's Hormozgan province. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12879-019-4661-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889522PMC
December 2019

Mode and tempo of human hepatitis virus evolution.

Comput Struct Biotechnol J 2019 25;17:1384-1395. Epub 2019 Oct 25.

Bioinformatics, Scientific Institute, IRCCS E. MEDEA, 23842 Bosisio Parini, Lecco, Italy.

Human viral hepatitis, a major cause of morbidity and mortality worldwide, is caused by highly diverse viruses with different genetic, ecological, and pathogenetic features. Technological advances that allow throughput sequencing of viral genomes, as well as the development of computational tools to analyze such genome data, have largely expanded our knowledge on the host range and evolutionary history of human hepatitis viruses. Thus, with the exclusion of hepatitis D virus, close or distant relatives of these human pathogens were identified in a number of domestic and wild mammals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.csbj.2019.09.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872792PMC
October 2019

Evaluation of the results of MOTAKK hepatitis C virus RNA genotyping and hepatitis delta virus external quality assessment programs during 2015-2016.

Turk J Gastroenterol 2019 Nov;30(11):957-963

Hepatology Institute, Ankara University, Ankara, Turkey.

Background/aims: To evaluate the HCV RNA genotyping and HDV RNA tests that are performed in molecular microbiology laboratories in Turkey as part of a national external quality assessment programme, MOTAKK (Moleküler Tanıda Kalite Kontrol) (English translation: Quality control in molecular diagnostics).

Materials And Methods: Plasmas having different HCV RNA genotypes were used to prepare HCV genotype control sera. The HDV RNA main stock was prepared from patients with chronic delta hepatitis who had a significant amount of viral load detected, as per the WHO reference materials on viral load studies that were compiled for the purpose of developing HDV RNA control sera. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/tjg.2019.18859DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883996PMC
November 2019

Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection.

J Viral Hepat 2020 Apr 9;27(4):428-436. Epub 2019 Dec 9.

Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

Noninvasive detection of cirrhosis via vibration-controlled transient elastography (VCTE) has revolutionized the management of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. However, VCTE has not been studied in chronic hepatitis D virus (HDV) infection and accuracy remains in question due to the significant hepatic inflammation associated with this infection. Consecutive HBV, HCV and HDV patients who underwent VCTE (2006-2019) were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080586PMC

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.

J Hepatol 2020 Mar 12;72(3):539-557. Epub 2019 Nov 12.

Hepatology Department, Hospices Civils de Lyon, INSERM U1052, University of Lyon, France.

Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary goal of developing agreement on chronic HBV treatment endpoints to guide clinical trials aiming to 'cure' HBV. Agreement among the conference participants was reached on some key points. 'Functional' but not sterilising cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable HBV DNA 6 months post-treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.11.003DOI Listing

Differences in delta virus hepatitis diagnosis methods and its effect on the hepatitis D prevalence.

Gut 2019 Nov 12. Epub 2019 Nov 12.

Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/gutjnl-2019-320159DOI Listing
November 2019
14.660 Impact Factor

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.

Hepatology 2019 Nov 12. Epub 2019 Nov 12.

Hepatology Department, Hospices Civils de Lyon, INSERM U1052, University of Lyon, France.

Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to guide clinical trials aiming to 'cure' HBV. Agreement among the conference participants was reached on some key points. 'Functional' but not sterilizing cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable HBV DNA 6 months post-treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.31030DOI Listing
November 2019

The heavy burden of hepatitis D in Uzbekistan.

Authors:
Francesco Negro

Liver Int 2019 11;39(11):2034-2035

Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14244DOI Listing
November 2019

HIV and the liver.

Top Antivir Med 2019 09;27(3):101-110

Johns Hopkins University, Baltimore, MD, USA.

Among individuals with HIV infection, liver disease remains an important cause of morbidity and mortality, even with the availability of agents that cure hepatitis C infection and suppress hepatitis B replication. The causes of liver disease are multifaceted and continue to evolve as the population ages and new etiologies arise. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis and hepatitis viruses such as A, D, and E have emerged even as hepatitis C has receded. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892621PMC
September 2019
1 Read